

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Taurador 10 mg/ml Solution for Injection for cattle, sheep & pigs

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

### Active substance:

Doramectin 10.0 mg

### Excipients:

| Qualitative composition of excipients and other constituents | Quantitative composition if that information is essential for proper administration of the veterinary medicinal product |
|--|---|
| Ethyl oleate   |   |
| Sesame oil, refined  |   |
| Butylhydroxyanisole (E320)                                   | 0.026 mg  |
| Butylhydroxytoluene (E321)                                   | 0.01 mg   |

Clear, colourless to yellow solution.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Cattle, Sheep and Pigs.

### 3.2 Indications for use for each target species

#### Cattle:

For the treatment of gastrointestinal roundworms, lungworms, warbles, lice, mange mites and eyeworms, listed below:

#### Gastrointestinal roundworms

*Ostertagia ostertagi* (L4, inhibited larvae and adult), *O. lyrata* (adult), *Haemonchus placei* (L4, adult), *Trichostrongylus axei* (L4, adult), *T. colubriformis* (L4, adult), *T. longispicularis* (adult), *Cooperia oncophora* (L4, adult), *C. pectinata* (adult), *C. punctata* (L4, adult), *C. surnabada* (syn. *mcmasteri*) (L4, adult), *Nematodirus spathiger* (adult), *Bunostomum phlebotomum* (adult), *Strongyloides papillosus* (adult), *Oesophagostomum radiatum* (L4, adult), *Trichuris* spp. (adult)

#### Lungworms

*Dictyocaulus viviparus* (L4, adult)

#### Eyeworms

*Thelazia* spp. (adult)

#### Warbles (parasitic stages)

*Hypoderma bovis*, *H. lineatum*

### Sucking lice

*Haematopinus eurysternus*, *Linognathus vituli*, *Solenopotes capillatus*

### Mange mites

*Psoroptes bovis*, *Sarcoptes scabiei*

The veterinary medicinal product also helps to treat:

### Gastrointestinal roundworms

*Nematodirus helvetianus*

### Mange mites

*Chorioptes bovis*

### Biting lice

*Damalinia bovis*

The veterinary medicinal product also helps to combat:

### Ticks

*Ixodes ricinus*

### Persistent activity

The veterinary medicinal product protects cattle against infections or re-infections due to the below listed parasites during the indicated periods:

| <u>Species</u>                  | <u>Prolonged activity</u> |
|---------------------------------|---------------------------|
| <i>Ostertagia ostertagi</i> :   | 28 days                   |
| <i>Cooperia oncophora</i> :     | 21 days                   |
| <i>Dictyocaulus viviparus</i> : | 35 days                   |
| <i>Linognathus vituli</i> :     | 28 days                   |
| <i>Psoroptes bovis</i> :        | 42 days                   |

### **Sheep:**

For the treatment of gastrointestinal roundworms, lungworms, mange mites and nasal bots listed below:

#### Gastrointestinal roundworms (adult, L4 larvae and L3 larvae, unless stated otherwise):

*Bunostomum trigonocephalum* (adult), *Chabertia ovina*, *Cooperia curticei* (L4 larvae), *C. oncophora* (adult, L4 larvae), *Gaigeria pachycelis*, *Haemonchus contortus*, *Nematodirus filicollis* (adult), *N. battus* (L4 larvae), *N. spathiger*, *Ostertagia (Teladorsagia) circumcincta*, *Ostertagia (Teladorsagia) trifurcata* (adult), *Oesophagostomum venulosum* (adult), *Oesophagostomum columbianum*, *Strongyloides papillosus*, *Trichostrongylus axei* (adult, L4 larvae), *Trichostrongylus colubriformis*, *Trichostrongylus vitrinus* (adult, L4 larvae), *Trichuris* spp. (adult)

#### Lungworms (adults, L4 larvae and L3 larvae, unless stated otherwise):

*Cystocaulus ocreatus* (adult), *Dictyocaulus filaria*, *Muellerius capillaris* (adult), *Neostrongylus linearis* (adult), *Protostrongylus rufescens* (adult)

#### Nasal bots (L1, L2 and L3 larvae)

*Oestrus ovis*

### Mange mites

*Psoroptes ovis*

**Pigs:**

For the treatment of gastrointestinal roundworms, lungworms, kidney worms, sucking lice and mange mites in pigs.

Gastrointestinal roundworms (adults and fourth stage larvae)

*Hyostrogylus rubidus*, *Ascaris suum*, *Strongyloides ransomi* (adults only), *Oesophagostomum dentatum*, *Oesophagostomum quadrispinulatum*

Lungworms

*Metastrongylus* spp. (adults only)

Kidney worms

*Stephanurus dentatus* (adults only)

Sucking lice

*Haematopinus suis*

Mange mites

*Sarcoptes scabiei* var. *suis*

The veterinary medicinal product protects pigs against infection or reinfection with *Sarcoptes scabiei* for 18 days.

**3.3 Contraindications**

Do not use in dogs, as severe adverse reactions may occur. In common with other avermectins, certain breeds of dogs, such as collies, and also tortoises, are especially sensitive to doramectin and particular care should be taken to avoid accidental consumption of the veterinary medicinal product.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

**3.4 Special warnings**

Unnecessary use of antiparasitics or use deviating from the instructions given in the SPC may increase the resistance selection pressure and lead to reduced efficacy. The decision to use the product should be based on confirmation of the parasitic species and burden, or of the risk of infestation based on its epidemiological features, for each herd/flock.

Repeated use for an extended period, particularly when using the same class of substances, increases the risk of resistance development. Within a herd/flock, maintenance of susceptible refugia is essential to reduce that risk. Systemically applied interval-based treatment and treatment of the whole herd/flock should be avoided. Instead, if feasible, only selected individual animals or subgroups should be treated (targeted selective treatment). This should be combined with appropriate husbandry and pasture management measures. Guidance for each specific herd/flock should be sought from the responsible veterinarian.

Resistance to doramectin and other avermectins has been reported in *Psoroptes ovis* in cattle and sheep and in gastro-intestinal nematodes, especially *T. longispicularis*, *Haemonchus* spp., *Cooperia* spp. and *Ostertagia ostertagi* in cattle and *Teladorsagia* spp., *Trichostrongylus* spp. and *Haemonchus* spp. in sheep.

The veterinary medicinal product can be used for the treatment of *Ostertagia (Teladorsagia) circumcincta* in sheep, including the inhibited L4 larval stages, especially strains resistant to benzimidazoles.

The use of this veterinary medicinal product should take into account local information about susceptibility of the target parasites, where available. It is recommended to further investigate cases of

suspected resistance using an appropriate diagnostic method (*e.g.* FECRT). Confirmed resistance should be reported to the marketing authorisation holder or to the competent authorities.

### **3.5 Special precautions for use**

#### Special precautions for safe use in the target species:

To avoid secondary reactions due to the death of *Hypoderma* larvae in the oesophagus or in the spine, it is recommended to administer the veterinary medicinal product at the end of the period of warble fly activity and before the larvae reach their resting site. Consult your veterinary surgeon on the correct timing of this treatment.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Take care to avoid accidental self-administration – seek medical attention should any specific signs be noticed.

Advice to medical practitioners: In case of accidental self-injection specific symptoms have rarely been observed and therefore any cases should be treated symptomatically.

This veterinary medicinal product can be irritating to eyes. Avoid accidental contact with the eyes, including hand-to-eye contact. In the case of accidental contact with the eyes rinse with plenty of water. The veterinary medicinal product may cause embryotoxicity and toxic effects to newborns via breastfeeding. Pregnant and breastfeeding woman should therefore take special care when handling this veterinary medicinal product.

Wash hands after use.

#### Special precautions for the protection of the environment:

Doramectin is very toxic to dung fauna and aquatic organisms and may accumulate in sediments.

The risk to aquatic ecosystems and dung fauna can be reduced by avoiding too frequent and repeated use of doramectin (and products of the same anthelmintic class).

The risk to aquatic ecosystems will be reduced by keeping treated animals away from water bodies for two to five weeks after treatment.

### **3.6 Adverse events**

None known.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

#### Pregnancy and lactation:

##### **Cattle and Sheep:**

May be used in pregnant cows and ewes.

##### **Pigs:**

Can be used in lactating sows.

#### Fertility:

##### **Pigs:**

Can be used in breeding sows and in breeding boars.

### **3.8 Interaction with other medicinal products and other forms of interaction**

None known.

### 3.9 Administration routes and dosage

Subcutaneous use (cattle).

Intramuscular use (sheep and pig).

#### Cattle

A single treatment of 1 ml (10 mg doramectin) per 50 kg bodyweight, equivalent to 200 µg/kg bodyweight, administered in the region of the neck by subcutaneous injection.

#### *Treatment schedule in regions where hypodermosis occurs*

Cattle with hypodermosis should be treated at the end of the period of warble fly activity and before the larvae reach their resting site.

#### Sheep

A single treatment of 1 ml (10 mg doramectin) per 50 kg bodyweight, equivalent to 200 µg/kg bodyweight, administered by intramuscular injection in the neck region.

#### Pigs

A single treatment of 0.3 ml (3 mg doramectin) per 10 kg bodyweight (1.0 ml per 33.0 kg) corresponding to 300 µg/kg bodyweight, administered by intramuscular injection.

Piglets weighing 16 kg or less should be treated according to the following table:

| <b>Body weight (kg)</b> | <b>Dose (ml)</b> |
|-------------------------|------------------|
| Less than 4kg           | 0.1ml            |
| 5 - 7 kg                | 0.2ml            |
| 8 - 10 kg               | 0.3ml            |
| 11 - 13 kg              | 0.4ml            |
| 14 - 16 kg              | 0.5ml            |

Underdosing could result in ineffective use and may favour resistance development.

To ensure a correct dosage, body weight should be determined as accurately as possible. If animals are to be treated collectively, reasonable homogeneous groups should be set up, and all animals of a group should be dosed at the rate corresponding to the heaviest one.

When treating groups of animals, use a suitable automatic dosing device and vented draw-off apparatus. Accuracy of the dosing device should be thoroughly checked.

For treatment of individual sheep or pigs, the use of appropriately sized needles and disposable syringes should be advised by a veterinarian. For the treatment of young lambs or piglets weighing 16kg or less, a 1mL disposable syringe graduated in increments of 0.1mL or less should be used.

Use dry, sterile equipment and follow aseptic procedures. Avoid introduction of contamination.

100 ml: The veterinary medicinal product is to be administered using a draw-off needle.

250 ml and 500 ml: Vial stoppers must not be broached more than 10 times with a 18G needle. Swab the septum before removing each dose.

Under cold conditions the veterinary medicinal product may be warmed to room temperature in a warm environment, to aid syringeability.

### 3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

Overdoses of up to 25 times the recommended dose in cattle, up to 15 times in sheep and up to 10 times in pigs have produced no particular clinical signs that could be attributed to treatment with doramectin.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

#### Cattle

Meat and offal: 70 days.

Not authorised for use in animals producing milk for human consumption.

Do not use in pregnant cows or heifers which are intended to produce milk for human consumption within 2 months of expected parturition.

#### Sheep

Meat and offal: 70 days.

Not authorised for use in animals producing milk for human consumption.

Do not use in pregnant ewes which are intended to produce milk for human consumption within 70 days of expected parturition.

#### Pigs

Meat and offal: 77 days.

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1 ATCvet code: QP54AA03**

### **4.2 Pharmacodynamics**

Doramectin is an antiparasitic agent, isolated from fermentation of selected strains derived from the soil organism *Streptomyces avermitilis*. It is a macrocyclic lactone and is closely related to ivermectin. Both compounds share a wide spectrum of antiparasitic activity and produce a similar paralysis in nematodes and parasitic arthropods. Macrocyclic lactones activate glutamate gated chloride channels (GluCl) found on muscle membranes of the pharynx and particular neurones of invertebrate parasites. Entry of chloride ions into roundworm excitatory motor neurons or arthropod muscle cells results in hyperpolarization and elimination of the transmission signal which results in paralysis. The selective toxicity of the macrocyclic lactones as antiparasitics is attributed to this action on channels that are not present in the host animal. There is evidence that the membranes of the muscle cells of the invertebrate female reproductive tract may be more sensitive to macrocyclic lactones than receptors on nerve or other muscle and this may explain the dramatic but temporary reduction in egg production in parasites not killed or eliminated by drug therapy. Several resistance mechanisms to macrocyclic lactones have been proposed, for example polymorphisms or changes in expression of the GluCl target and transport protein genes, and to the increased expression of encoding drug-metabolizing enzymes. In addition, decreased expression of drug target genes may lead to a reduction of drug-binding sites and thus reduced drug effectiveness.

### **4.3 Pharmacokinetics**

In cattle, maximum plasma concentration of Doramectin occurs 3 days after subcutaneous administration. The elimination half-life is around 6 days,

In sheep, maximum plasma concentration of Doramectin occurs 2 days after intramuscular administration. The elimination half-life is 4.5 days in sheep,

In pigs, maximum plasma concentration of Doramectin occurs 3 days after intramuscular administration of the veterinary medicinal product. The elimination half-life is around 6 days.

## **Environmental properties**

Like other macrocyclic lactones, doramectin has the potential to adversely affect non-target organisms. Following treatment, excretion of potentially toxic levels of doramectin may take place over a period of several weeks. Faeces containing doramectin excreted onto pasture by treated animals may reduce the abundance of dung feeding organisms which may impact on the dung degradation.

Doramectin is very toxic to aquatic organisms and may accumulate in sediments. Doramectin is very persistent in soils.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf life after first opening the immediate packaging:

100 ml: use immediately. Discard any unused material after first opening the primary packaging;

250 ml and 500 ml: 28 days.

### **5.3 Special precautions for storage**

Store in the original package.

### **5.4 Nature and composition of immediate packaging**

Multi-dose amber glass vials (Type II) closed with a nitrile rubber stopper and sealed with an aluminium cap in a protective plastic container.

#### Package Sizes:

Protective plastic container with 1 x 100 ml vial.

Protective plastic container with 1 x 250 ml vial.

Protective plastic container with 1 x 500 ml vial.

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

The veterinary medicinal product should not enter water courses as doramectin is extremely dangerous for fish and other aquatic organisms.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Norbrook Laboratories (Ireland) Limited

**7. MARKETING AUTHORISATION NUMBER(S)**

VPA 22664/151/001

**8. DATE OF FIRST AUTHORISATION**

22/11/2024

**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

10/02/2026

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).